White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI


The success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also possible budgetary impacts of testing and regulatory requirements. Gaining a better understanding of what is involved in the cost of a clinical trial can help the entire process, enabling your procurement and finance teams to more accurately budget and execute the tasks needed for success.
In this paper we will demonstrate how using image analysis (IA) and implementing biomarker assessment can improve your return on investment (ROI), accelerate trials, and minimize budget impacts.

To learn more…

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

Flagship Biosciences Is Honored with a Best Practices Award

We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...

Flagship Biosciences hires Tom Turi, Ph.D. as CSO

Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...